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Abstract Proteins belonging to the peroxisome proliferator-
activated receptor γ coactivator 1 (PGC-1) family are key
regulators of cellular energy homeostasis in a number of
oxidative tissues, including skeletal muscle. While the
regulation and function of PGC-1α seems central to muscle
fibre plasticity in endurance exercise, the role of PGC-1β in
this tissue is less clear. Wright et al. (Diabetologia, DOI:
10.1007/s00125-011-2068-x) provide evidence for a protec-
tive effect of moderately elevated PGC-1β in electroporated
rat skeletal muscle against high-fat-diet-induced insulin
resistance, at least in part by promoting the oxidation of
long chain acyl-CoA entities and the elimination of reactive
oxygen species. These data provide important insights into
the biological role of PGC-1β in skeletal muscle and imply
novel therapeutic avenues for improving peripheral insulin
sensitivity.
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Adequate skeletal muscle oxidative capacity and mitochon-
drial function are crucial for maintaining systemic glucose
and insulin levels and, accordingly, the regulation of these
processes is tightly controlled. In recent years, the three
members of the peroxisome proliferator-activated receptor γ
coactivator 1 (PGC-1) family of transcriptional coactiva-
tors have emerged as central regulators of energy
homeostasis in muscle and other tissues. Pgc-1α (also
known as Ppargc1a) gene expression and the levels and
activity of the protein are affected by almost all of the
signalling pathways that are activated in the contracting
muscle fibres [1]. In turn, PGC-1α controls the adaptive
changes elicited by endurance training [1]. In contrast to the
more detailed information available on PGC-1α, much less
is known about PGC-1β and the PGC-1-related coactivator.
While relative level of physical activity is the dominant
regulator of Pgc-1α gene expression in skeletal muscle,
transcriptional control of Pgc-1β (also known as Ppargc1b)
seems less straightforward, and different effects of exercise,
denervation, dietary restriction, bariatric surgery, obesity
and insulin stimulation on muscle Pgc-1β mRNA levels
have been described, some with conflicting results in
different experimental settings (summarised in references
[1–4]). The elegant study by Wright et al. published in this
issue of Diabetologia [2] sheds more light on the important
role of PGC-1β in muscle physiology. Pgc-1β was over-
expressed in electroporated tibialis cranialis and extensor
digitorum longus muscles of low-fat- or high-fat-fed rats
(Fig. 1). Despite the very moderate increase in PGC-1β
levels, a significant elevation in mitochondrial oxidative
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capacity, reactive oxidative species detoxification and lipid
metabolism ensued. Importantly though, ectopic expression
of PGC-1β in the high-fat-fed rats also boosted insulin
sensitivity. While a causal link between reduced insulin
resistance and the observed induction of long-chain acyl-
CoA metabolism and antioxidant defence by PGC-1β was
not examined, these long-chain acyl-CoA and reactive
oxygen species are likely to contribute to the development
of muscle insulin resistance [5].
Dysregulation of PGC-1α and PGC-1β gene expression
levels has been found in the skeletal muscle of type 2
diabetic patients and individuals with impaired glucose
tolerance, at least in some populations [6, 7]. Studies in
skeletal muscle-specific knockout mice for Pgc-1α or
Pgc-1β alone failed to show a direct involvement of genetic
ablation of the individual coactivators in the aetiology of
insulin resistance in this tissue [8–10]. The consequence of
a Pgc-1α/Pgc-1β muscle-specific double knockout ap-
proach remains unknown. In contrast, the data provided by
Wright et al. [2] suggest a protective role for PGC-1β
against high-fat-diet-induced insulin resistance in skeletal
muscle. Similarly, the moderate and acute modulation of
electroporated PGC-1α in muscle resulted in improvement
of insulin sensitivity in the muscle of lean and obese Zucker
rats [11]. Interestingly, the exact opposite observation, i.e. a
more rapidly progressing insulin resistance, was reported
for high-fat-fed muscle-specific Pgc-1α transgenic mice
[12]. The electroporation-based approach used by Wright et
al. [2] to increase PGC-1β levels in individual muscles
differs from the use of muscle-specific transgenic animals,
which produces a stronger, chronic elevation of PGC-1β
[13]. Thus, potentially confounding effects caused by the
strong transgenic expression—such as the strong inhibition
of Pgc-1α gene expression in the Pgc-1β muscle-specific
transgenic animals [13] that could contribute to the muscle
fibre-type switch observed in these mice—were not
encountered by Wright et al. Taking into consideration
their findings and the previous work by Bonen et al. [11],
Wright et al. propose that a moderate acute elevation of
PGC-1α or PGC-1β restores insulin sensitivity, at least in
glycolytic muscles in rats. Accordingly, modulation of
PGC-1α and PGC-1β gene expression might be an
attractive novel therapeutic option against type 2 diabetes.
However, designing pharmacological interventions aimed at
the PGC-1 coactivators is not a trivial task [3]. First, the
chemical entities that selectively induce PGC-1α or PGC-1β
gene expression in skeletal muscle remain elusive. Second,
pharmacological methods that alter PGC-1 levels must
achieve a concentration within a therapeutically benefi-
cial window in order to avoid the detrimental effects
associated with inadequate or excessive PGC-1 levels
[3]. Finally, some paradoxical findings about the PGC-1
coactivators in muscle remain unexplained. For example,
in the present study [2], Pgc-1β expression and oxidative
metabolism are already increased as a consequence of the
high-fat diet, and it is unclear how further elevation of
PGC-1β levels exerts the observed amelioration of insulin
sensitivity. Moreover, while ectopic PGC-1β lowers the
long-chain acyl-CoA pool in muscle, the high-fat-diet-
induced elevation of intramuscular ceramide and diacyl-
glycerol, both strongly implicated in causing insulin
resistance [5], is unaffected. It is also unclear how the
chronic vs acute and moderate vs strong expression of
Pgc-1α and Pgc-1β differ mechanistically and, at least in
the case of Pgc-1α, result in diametrically opposite
outcomes in terms of peripheral insulin sensitivity.
Whether this is also true for Pgc-1β is unclear, since the
effect of the transgenic expression of Pgc-1β in muscle on
insulin resistance has not yet been elucidated [13].
Therefore, more studies are needed to fundamentally
understand the regulation and function of the PGC-1
proteins in skeletal muscle before an appropriate drug-
targeting strategy aimed at these coactivators can be
attempted.
Fig. 1 Overexpression of Pgc-1β in glycolytic rat skeletal muscles
improves insulin sensitivity. a A high-fat diet promotes the increase in
intramuscular levels of ceramide, diacylglycerol (DAG), long-chain
acyl CoA entities (LCACoA) and reactive oxygen species (ROS), all
of which contribute to the development of insulin resistance. The
reason for the increase in mitochondrial function and Pgc-1β
expression in the muscle of high-fat-fed rats remains unclear. It is
conceivable that the resulting boost in fatty acid oxidation is an
adaptive compensatory, yet inadequate, mechanism to deal with the
lipid overload. b Ectopic expression of Pgc-1β in electroporated
glycolytic rat muscles results in increased mitochondrial function,
fatty acid metabolism and antioxidant defence. As a consequence,
LCACoA levels are lowered. Despite the inability of ectopic PGC-1β
to reduce intramuscular ceramide and DAG, an improvement in
insulin sensitivity is achieved
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